New Roche CEO Thomas Schinecker is implementing a refined R&D strategy for the sprawling Swiss conglomerate in the wake of several recent late-stage failures.
The new goals aim to ensure pipeline programs can move more efficiently from early-stage to late-stage, while the company also hunts for deals on drugs already being tested in human trials, Schinecker said Monday during Roche’s Pharma Day in London.
“We need to deliver value fast, and that’s the mentality we want in the organization,” the CEO said.
What is the name of the Roche for atezolizumab?The active substance in Tecentriq, atezolizumab, is a monoclonal antibody (a type of protein) designed to attach to a protein called PD-L1, which is present on many cancer cells.
PD1-Vaxx may just fit your criteria Tom?.....
New Roche CEO Thomas Schinecker is implementing a refined R&D...
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |